Last checked at 25 Mar 2024 07:23
AstraZeneca gets FDA approval for Ultomiris treatment
(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News5
AZN Share
Chat
AZN Share
Trades16,630
AZN
Live RNS2
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,024.00
Bid:
12,024.00
Ask:
12,028.00
Change:
36.00 (0.30%)
Spread:
4.00 (0.033%)
Open:
12,254.00
High:
12,256.00
Low:
12,018.00
Prev. Close:
11,988.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca sells antibiotics business to Pfizer for £1.2bn
Wed, 24th Aug 2016 07:11
(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales.The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main therapy areas, while realising value from what it said was a strong portfolio of established and late-stage antibiotics through Pfizer's commercialisation and development abilities.An up-front payment of $550m on completion of the deal, which is expected in the fourth quarter of 2016, will be followed by an unconditional payment of $175m in January 2019 for the commercialisation and development rights to approved antibiotics Merrem, Zinforo and Zavicefta, as well as two still in development, ATM-AVI and CXL.Furthermore, Pfizer will pay up to $250m in commercial, manufacturing and regulatory milestones, up to $600m in sales-related payments as well as recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.AstraZeneca, which generated product sales from Merrem and Zinforo in 2015 of $250m, said the agreement does not impact its financial guidance for 2016 and stressed that MedImmune's portfolio of biologic products such as FluMis and Synagis, and AstraZeneca's stake in Entasis Therapeutics, spun-off in 2015 and now operating as a stand-alone company, are not included as part of the agreement."This agreement reinforces our strategic focus to invest in our three main therapy areas where we can make the greatest difference to patients' lives," said Luke Miels, AstraZeneca's executive vice president for Europe and head of the antibiotics business unit."We're pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer's dedicated focus on infectious diseases, ensuring these important medicines reach greater numbers of patients around the world."
More News
21 Mar 2024 16:43
AstraZeneca's Tagrisso successful in treating lung cancer
(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.
Read more19 Mar 2024 08:56
TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion
(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.
Read more19 Mar 2024 07:05
AstraZeneca to buy US-listed Fusion Phrama for $2bn
(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Read more18 Mar 2024 16:09
UK dividends calendar - next 7 days
| Tuesday 19 March | |
| Jarvis Securities PLC | dividend payment date |
| Wednesday 20 March | |
| Virgin Money UK PLC | dividend payment date |
| Thursday 21 March | |
| abrdn Asia Focus PLC | dividend payment date |
| abrdn Private Equity Opportunities Trust PLC | ex-dividend payment date |
| AIB Group PLC | ex-dividend payment date |
| Beazley PLC | ex-dividend payment date |
| BlackRock World Mining Trust PLC | ex-dividend payment date |
| British American Tobacco PLC | ex-dividend payment date |
| Chemring Group PLC | ex-dividend payment date |
| CLS Holdings PLC | ex-dividend payment date |
| Conduit Holdings Ltd | ex-dividend payment date |
| Craneware PLC | ex-dividend payment date |
| Crest Nicholson Holdings PLC | ex-dividend payment date |
| Diverse Income Trust PLC | ex-dividend payment date |
| Fonix Mobile PLC | ex-dividend payment date |
| FW Thorpe PLC | ex-dividend payment date |
| Glanbia PLC | ex-dividend payment date |
| GlobalData PLC | ex-dividend payment date |
| Globalworth Real Estate Investments Ltd | ex-dividend payment date |
| Goodwin PLC | ex-dividend payment date |
| Gore Street Energy Storage Fund PLC | ex-dividend payment date |
| Hargreaves Services PLC | ex-dividend payment date |
| HgCapital Trust PLC | ex-dividend payment date |
| Hikma Pharmaceuticals PLC | ex-dividend payment date |
| Jardine Matheson Holdings LD | ex-dividend payment date |
| London Finance & Investment Group PLC | ex-dividend payment date |
| Maven Income & Growth VCT 3 PLC | ex-dividend payment date |
| Maven Income & Growth VCT 5 PLC | ex-dividend payment date |
| MTI Wireless Edge Ltd | ex-dividend payment date |
| Nichols PLC | ex-dividend payment date |
| NWF Group PLC | ex-dividend payment date |
| Palace Capital PLC | ex-dividend payment date |
| Pearson PLC | ex-dividend payment date |
| Pembroke VCT B PLC | ex-dividend payment date |
| Primorus Investments PLC | ex-dividend payment date |
| Schroders PLC | ex-dividend payment date |
| Triple Point Energy Transition PLC | ex-dividend payment date |
| Tristel PLC | ex-dividend payment date |
| VPC Specialty Lending Investments PLC | dividend payment date |
| Friday 22 March | |
| easyJet PLC | dividend payment date |
| FRP Advisory Group PLC | dividend payment date |
| Gulf Investment Fund PLC | dividend payment date |
| Henderson Opportunities Trust PLC | dividend payment date |
| Hercules Site Services PLC | dividend payment date |
| Impax Asset Management Group PLC | dividend payment date |
| JLEN Environmental Assets Group Ltd | dividend payment date |
| JPMorgan Multi-Asset Growth & Income PLC | dividend payment date |
| Mattioli Woods PLC | dividend payment date |
| Mobeus Income & Growth 2 VCT PLC | dividend payment date |
| Mobeus Income & Growth 4 VCT PLC | dividend payment date |
| Ramsdens Holdings PLC | dividend payment date |
| Riverstone Credit Opportunities Income PLC | dividend payment date |
| Ruffer Investment Co Ltd | dividend payment date |
| Samuel Heath & Sons PLC | dividend payment date |
| Troy Income & Growth Trust PLC | dividend payment date |
| Unilever PLC | dividend payment date |
| Monday 25 March | |
| AstraZeneca PLC | dividend payment date |
| Endeavour Mining PLC | dividend payment date |
| Mountview Estates PLC | dividend payment date |
| Shell PLC | dividend payment date |
| Comments and questions to newsroom@alliancenews.com | |
| A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
18 Mar 2024 14:08
AstraZenca hails Imfinzi and Lynparza results on endometrial cancer
(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.
Read more14 Mar 2024 10:01
TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion
(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.
Read more14 Mar 2024 07:52
LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook
(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.
Read more14 Mar 2024 07:16
AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn
(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.
Read more8 Mar 2024 06:00
Astra, Sanofi's antibody 90% effective against RSV in infants - CDC
(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.
Read more6 Mar 2024 14:40
UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted
(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.
Read more5 Mar 2024 14:24
AstraZeneca's breast cancer treatment blocked for NHS use in England
(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.
Read more4 Mar 2024 09:31
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.
Read more4 Mar 2024 07:18
AstraZeneca's chemo replacement treatment moves closer to EU approval
(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.
Read more26 Feb 2024 08:51
AstraZeneca's Voydeya treatment recommended for EU approval
(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.
Read more